PE/Cy5® Anti-CD45.1 antibody [A20] (ab25349)

Submit a review Submit a question References (2)

Key features and details

  • PE/Cy5® Mouse monoclonal [A20] to CD45.1
  • Reacts with: Mouse
  • Conjugation: PE/Cy5®. Ex: 496nm, Em: 670nm
  • Isotype: IgG2a

Overview

  • Product name

    PE/Cy5® Anti-CD45.1 antibody [A20]
    See all CD45.1 primary antibodies

  • Description

    PE/Cy5® Mouse monoclonal [A20] to CD45.1

  • Host species

    Mouse

  • Conjugation

    PE/Cy5®. Ex: 496nm, Em: 670nm

  • Specificity

    The monoclonal antibody A20 recognizes all mouse leukocytes expressing the CD 45.1 allotype.

  • Species reactivity

    Reacts with: Mouse

  • Immunogen

    The details of the immunogen for this antibody are not available.

  • General notes

    This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Target

  • Relevance

    CD45 is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation.

  • Cellular localization

    Type I membrane protein.

  • Database links

    • Alternative names

      • B220 antibody
      • CD45 antibody
      • CD45 antigen antibody
      • CD45R antibody
      • GP180 antibody
      • L-CA antibody
      • LCA antibody
      • LY5 antibody
      • Protein tyrosine phosphatase receptor type C antibody
      • Protein tyrosine phosphatase, receptor type, c polypeptide antibody
      • Receptor type tyrosine protein phosphatase C antibody
      • T200 antibody
      • T200 glycoprotein antibody
      • T200 leukocyte common antigen antibody
      see all

    References (2)

    Publishing research using ab25349? Please let us know so that we can cite the reference in this datasheet.

    ab25349 has been referenced in 2 publications.

    • Mardiney M & Malech HL Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 87:4049-56 (1996). PubMed: 8639760
    • Vallera DA  et al. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249-56 (1994). PubMed: 7906058

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab25349.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com